Altered phosphorylation of topoisomerase I following overexpression in an ovarian cancer cell line

Biochemistry and Cell Biology

Volumn 84, Issue 1, 2006, Pages 55-66

  St Amant, Christiane ^a   Lussier, Stéphanie ^a   Lehoux, Jacques ^a   Laberge, Rémi Martin ^a   Boissonneault, Guylain ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Camptothecins; Chemotherapy; Ovarian cancer; Phosphorylation; Topoisomerase I

Indexed keywords

CHEMOTHERAPY; ENZYMES; ISOMERIZATION; TUMORS; VIRUSES;

CAMPTOTHECINS; OVARIAN CANCER; PHOSPHORYLATION; TOPOISOMERASE I;

CELLS;

ALKALINE PHOSPHATASE; DNA TOPOISOMERASE; TOPOTECAN;

ADENOVIRUS; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENSITIVITY ANALYSIS;

ADENOVIRIDAE; CELL DEATH; DNA TOPOISOMERASES, TYPE I; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION; HUMANS; NUCLEIC ACID CONFORMATION; OVARIAN NEOPLASMS; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; TOPOTECAN; TUMOR CELLS, CULTURED;

ADENOVIRIDAE;

EID: 33645423160     PISSN: 08298211     EISSN: None     Source Type: Journal    
DOI: 10.1139/o05-157     Document Type: Article

References (58)

1. Beidler, D.R., and Cheng, Y.C. 1995. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol. Pharmacol. 47: 907-914.
2. Beshara, N., Fung Kee Fung, M., and Faught, W. 2002. The role of topotecan as second-line therapy in patients with recurrent ovarian cancer. Eur. J. Gynaecol. Oncol. 23: 287-290.
3. Bjornsti, M.A., Benedetti, P., Viglianti, G.A., and Wang, J.C. 1989. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res. 49: 6318-6323.
4. Brogden, R.N., and Wiseman, L.R. 1998. Topotecan. A review of its potential in advanced ovarian cancer. Drugs, 56: 709-723.
5. Buckwalter, C.A., Lin, A.H., Tanizawa, A., Pommier, Y.G., Cheng, Y.C., and Kaufmann, S.H. 1996. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer Res. 56: 1674-1681.
6. Cardellini, E., and Durban, E. 1993. Phosphorylation of human topoisomerase I by protein kinase C in vitro and in phorbol 12-myristate 13-acetate-activated HL-60 promyelocytic leukaemia cells. Biochem. J. 291: 303-307.
7. Cardellini, E., Bramucci, M., Gianfranceschi, G.L., and Durban, E. 1994. Human topoisomerase I is phosphorylated in vitro on its amino terminal domain by protein kinase NII. Biol. Chem. Hoppe-Seyler 375: 255-259.
8. Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., and Nishizuka, Y. 1982. Direct activation of calcium-activated, phospholipid- dependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem. 257: 7847-7851.
9. Chang, J.Y., Dethlefsen, L.A., Barley, L.R., Zhou, B.S., and Cheng, Y.C. 1992. Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem. Pharmacol. 43: 2443-2452.
10. Christensen, M.O., Barthelmes, H.U., Feineis, S., Knudsen, B.R., Andersen, A.H., Boege, F., and Mielke, C. 2002. Changes in mobility account for camptothecin-induced subnuclear relocation of topoisomerase I. J. Biol. Chem. 277: 15661-15665.
11. Cree, I.A., Knight, L., Di Nicolantonio, F., Sharma, S., and Gulliford, T. 2002. Chemosensitization of solid tumors by modulation of resistance mechanisms. Curr. Opin. Invest. Drugs 3: 634-640.
12. D'Arpa, P., and Liu, L.F. 1995. Cell cycle-specific and transcription-related phosphorylation of mammalian topoisomerase I. Exp. Cell Res. 217: 125-131.
13. D'Arpa, P., Beardmore, C., and Liu, L.F. 1990. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 50: 6919-6924.
14. Danks, M.K., Garrett, K.E., Marion, R.C., and Whipple, D.O. 1996. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res. 56: 1664-1673.
15. Desai, S.D., Liu, L.F., Vazquezabad, D., and Darpa, P. 1997. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J. Biol. Chem. 272: 24159-24164.
16. Desai, S.D., Li, T.K., Rodriguez-Bauman, A., Rubin, E.H., and Liu, L.F. 2001. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 61: 5926-5932.
17. Durban, E., Goodenough, M., Mills, J., and Busch, H. 1985. Topoisomerase I phosphorylation in vitro and in rapidly growing Novikoff hepatoma cells. EMBO J. 4: 2921-2926.
18. Edwards, T.K., Saleem, A., Shaman, J.A., Dennis, T., Gerigk, C., Oliveros, E. et al. 2000. Role for nucleolin/Nsr1 in the cellular localization of topoisomerase I. J. Biol. Chem. 275: 36181-36188.
19. Gupta, M., Fujimori, A., and Pommier, Y. 1995. Eukaryotic DNA topoisomerase I. Biochim. Biophys. Acta, 1262: 1-14.
20. Hann, C., Evans, D.L., Fertala, J., Benedetti, P., Bjornsti, M.A., and Hall, D.J. 1998. Increased camptothecin toxicity induced in mammalian cells expressing Saccharomyces cerevisiae DNA topoisomerase I. J. Biol. Chem. 273: 8425-8433.
21. Hasegawa, S., Abe, T., Naito, S., Kotoh, S., Kumazawa, J., Hipfner, D.R. et al. 1995. Expression of multidrug resistance-associated protein (Mrp), Mdr1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br. J. Cancer, 71: 907-913.
22. He, T.C., Zhou, S., da Costa, L.T., Yu, J., Kinzler, K.W., and Vogelstein, B. 1998. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U.S.A. 95: 2509-2514.
23. Hendricks, C.B., Rowinsky, E.K., Grochow, L.B., Donehower, R.C., and Kaufmann, S.H. 1992. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res. 52: 2268-2278.
24. Hsiang, Y.H., and Liu, L.F. 1988. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48: 1722-1726.
25. Hsiang, Y.H., Hertzberg, R., Hecht, S., and Liu, L.F. 1985. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260: 14873-14878.
26. Hsiang, Y.H., Lihou, M.G., and Liu, L.F. 1989. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49: 5077-5082.
27. Kaiserman, H.B., Ingebritsen, T.S., and Benbow, R.M. 1988. Regulation of Xenopus laevis DNA topoisomerase I activity by phosphorylation in vitro. Biochemistry, 27: 3216-3222.
28. Kanzawa, F., Sugimoto, Y., Minato, K., Kasahara, K., Bungo, M., Nakagawa, K. et al. 1990. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res. 50: 5919-5924.
29. Kijima, T., Kubota, N., and Nishio, K. 1994. Establishment of a CPT-11-resistant human ovarian cancer cell line. Anticancer Res. 14: 799-803.
30. Kordiyak, G.J., Jakes, S., Ingebritsen, T.S., and Benbow, R.M. 1994. Casein kinase II stimulates Xenopus laevis DNA topoisomerase I by physical association. Biochemistry, 33: 13484-13491.
31. Larsen, A.K., and Skladanowski, A. 1998. Cellular resistance to topoisomerase-targeted drug: from drug uptake to cell death. Biochim. Biophys. Acta, 1400: 257-274.
32. Latorre, A., De Lena, M., Catino, A., Crucitta, E., Sambiasi, D., Guida, M. et al. 2002. Epithelial ovarian cancer: second and third line chemotherapy. Int. J. Oncol. 21: 179-186.
33. Liu, L.F. 1989. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58: 351-375.
34. Ma, J., Maliepaard, M., Nooter, K., Loos, W.J., Kolker, H.J., Verweij, J. et al. 1998. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br. J. Cancer, 77: 1645-1652.
35. Madden, K.R., and Champoux, J.J. 1992. Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res. 52: 525-532.
36. Maliepaard, M., van Gastelen, M.A., de Jong, L.A., Pluim, D., van Waardenburg, R.C., Ruevekamp-Helmers, M.C. et al. 1999. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 59: 4559-4563.
37. Mao, Y., Mehl, I.R., and Muller, M.T. 2002. Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status. Proc. Natl. Acad. Sci. U.S.A. 99: 1235-1240.
38. Mattern, M.R., Hofmann, G.A., Polsky, R.M., Funk, L.R., McCabe, F.L., and Johnson, R.K. 1993. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol. Res. 5: 467-474.
39. Mo, Y.Y., Wang, P., and Beck, W.T. 2000. Functional expression of human DNA topoisomerase I and its subcellular localization in HeLa cells. Exp. Cell Res. 256: 480-490.
40. Mo, Y.Y., Yu, Y., Shen, Z., and Beck, W.T. 2002. Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein. J. Biol. Chem. 277: 2958-2964.
41. Pommier, Y., Kerrigan, D., Hartman, K.D, and Glazer, R.I. 1990. Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C. J. Biol. Chem. 265: 9418-9422.
42. Pommier, Y., Pourquier, P., Fan, Y., and Strumberg, D. 1998. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta, 1400: 83-106.
43. Pourquier, P., and Pommier, Y. 2001. Topoisomerase I-mediated DNA damage. Adv. Cancer Res. 80: 189-216.
44. Rallabhandi, P., Hashimoto, K., Mo, Y.Y., Beck, W.T., Moitra, P.K., and D'Arpa, P. 2002. Sumoylation of topoisomerase I is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin. J. Biol. Chem. 277: 40020-40026.
45. Rasheed, Z.A., and Rubin, E.H. 2003. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene, 22: 7296-7304.
46. Rothenberg, M.L. 1997. Topoisomerase I inhibitors: review and update. Ann. Oncol. 8: 837-855.
47. Samuels, D.S., Shimizu, Y., and Shimizu, N. 1989. Protein kinase C phosphorylates DNA topoisomerase I. FEBS Lett. 259: 57-60.
48. Samuels, D.S., Shimizu, Y., Nakabayashi, T., and Shimizu, N. 1994. Phosphorylation of DNA topoisomerase I is increased during the response of mammalian cells to mitogenic stimuli. Biochim. Biophys. Acta, 1223: 77-83.
49. Schreiber, E., Matthias, P., Muller, M.M., and Schaffner, W. 1989. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 17: 6419.
50. Staron, K., and Samuels, D.S. 1998. Phosphorylation of serine residues in the N-terminal domains of eukaryotic type I topoisomerases. Mol. Biol. Rep. 25: 157-161.
51. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Isoe, T., and Tsuruo, T. 1990. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 50: 6925-6930.
52. Tan, K.B., Mattern, M.R., Eng, W.K., McCabe, F.L., and Johnson, R.K. 1989. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J. Natl. Cancer Inst. 81: 1732-1735.
53. Thielmann, H.W., Popanda, O., and Staab, H.J. 1999. Subnuclear distribution of DNA topoisomerase I and Bax protein in normal and xeroderma pigmentosum fibroblasts after irradiation with UV light and gamma rays or treatment with topotecan. J. Cancer Res. Clin. Oncol. 125: 193-208.
54. Turman, M.A., and Douvas, A. 1993. A casein kinase type-II (CkII)-like nuclear protein kinase associates with, phosphorylates, and activates topoisomerase-I. Biochem. Med. Metab. Biol. 50: 210-225.
55. Wadkins, R.M., Danks, M.K., Horowitz, L., and Baker, S.D. 1998. Characterization of topotecan-mediated redistribution of DNA topoisomerase I by digital imaging microscopy. Exp. Cell Res. 241: 332-339.
56. Wang, L.F., Ting, C.Y., Lo, C.K., Su, J.S., Mickley, L.A., Fojo, A.T. et al. 1997. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. Cancer Res. 57: 1516-1522.
57. Woo, M.H., Vance, J.R., Marcos, A.R., Bailly, C., and Bjornsti, M.A. 2002. Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin. J Biol. Chem. 277: 3813-3822.
58. Yu, D., Khan, E., Khaleque, M.A., Lee, J., Laco, G., Kohlhagen, G. et al. 2004. Phosphorylation of DNA topoisomerase I by the c-Abl tyrosine kinase confers camptothecin sensitivity. J Biol. Chem. 279: 51851-51861.